Thank you to all that answered my last post about the potential competition for GNTA. It will indeed be interesting to watch the progress of these various companies and their differing approaches to curing cancer. This is a very important topic.
While I still am not sure where most of my money should go in the cancer vaccine/treatment race. I think there is a very interesting side issue: immune system response.
I think that everyone would agree that a drug used in conjunction with a cancer vaccine or treatment that could seriously boost immune response would be an excellent addition to the medical coctail. I believe such a drug exists and is already being marketed in I believe 13 countries. It is in phase 2 in the U.S. It is called Zadaxin and is made by Sciclone Pharmaceuticals (SCLN). Not only does it significantly boost immune response, it has NO negative side effects. I believe g3139 would be even more effective when used in combination with this drug. By the way, Zadaxin is also being used in anti-AIDS cocktails too. Lastly, and far from least important, Zadaxin looks like it will be the best selling, most effective drug for Hep B and Hep C.
For those of you that don't want to put all your eggs in one anti-cancer basket, you might want to take a look at SCLN's Zadaxin because of its ability to be used in concert with many different therapies. This company also has a nice drug for CF in phase 2. All this and a market cap of 200 million (unbelievable).
I think I'll probably pick up some GNTA over the next week or two. I'll also accumulate my position in a few of the other lead cancer treatment companies. These shares in combination with my SCLN holdings should perform very nicely in the coming 1-2 years.